微创冠状动脉搭桥治疗多支冠脉病变临床效果及桥血管通畅率分析

Clinical outcome and graft patency of minimally invasive coronary artery bypass grafting for treatment of multi-vessel disease

目的 总结分析微创冠状动脉搭桥技术治疗多支冠脉病变的临床效果及移植血管通畅率.方法 2016年12月至2017年4月,12例多支冠状动脉血管病变的患者于我科接受微创冠状动脉搭桥治疗,对患者围手术期资料及治疗结果进行分析,总结微创冠状动脉搭桥的治疗效果.结果 12例患者均顺利接受微创冠状动脉搭桥治疗.术中共完成远端吻合口26个.术中经左前外侧胸部小切口在直视下获取左侧乳内动脉与前降支搭桥,内窥镜获取下肢大隐静脉连接于升主动脉后与其他冠状动脉搭桥.无患者手术中转为开胸手术.术后呼吸机使用时间（7.6±4.2）h,监护室停留时间（22.4±8.2）h.10例患者未输血,占83.3％（10/12）.造影提示25（25/26,96.2％）个桥吻合口通畅.住院期间无死亡、心肌梗死、脑卒中等发生.结论 微创冠状动脉搭桥技术治疗多支冠脉病变安全有效,术后早期造影显示桥血管通畅率满意.

Objective This study was to investigate clinical outcome and graft patency of minimally invasive coronary artery bypass grafting procedure as novel treatment for multi-vessel disease.Methods From Dec 2016 to Apr 2017,the data of 12 patients underwent MICS CABG were analyzed.Perioperative data,clinic outcome and graft patency data were collected and analyzed.Results 12 patients underwent successful MICS CABG.Postoperative mechanical ventilation time was （7.6±4.2）h,mean intensive care unit stay time was （22.4±8.2）h.10 patients （10/12,83.3%） had not transfusion of blood product.Postoperative angiography revealed 25/26 （96.2%） patent anastomosis.No death,myocardial infarction or stroke occurred during hospitalization.Conclusion MICS CABG is safe and effective treatment for multi-vessel disease with good clinical outcome and postoperative graft patency.